AGENUS INC (AGEN)
US00847G7051 - Common Stock
Overall AGEN gets a fundamental rating of 1 out of 10. We evaluated AGEN against 612 industry peers in the Biotechnology industry. Both the profitability and financial health of AGEN have multiple concerns. AGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AGEN has reported negative net income.
AGEN had a negative operating cash flow in the past year.
In the past 5 years AGEN always reported negative net income.
In the past 5 years AGEN reported 4 times negative operating cash flow.
1.2 Ratios
The profitability ratios for AGEN are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AGEN has a Gross Margin of 89.38%. This is amongst the best in the industry. AGEN outperforms 91.72% of its industry peers.
AGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM | N/A | ||
| GM | 89.38% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGEN has more shares outstanding
AGEN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AGEN is higher compared to a year ago.
2.2 Solvency
AGEN has an Altman-Z score of -7.82. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.
AGEN's Altman-Z score of -7.82 is on the low side compared to the rest of the industry. AGEN is outperformed by 75.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.82 |
ROIC/WACCN/A
WACC9.39%
2.3 Liquidity
AGEN has a Current Ratio of 0.84. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of AGEN (0.84) is worse than 92.55% of its industry peers.
AGEN has a Quick Ratio of 0.84. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.84, AGEN is doing worse than 91.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
AGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1314.29%.
The Revenue for AGEN has decreased by -68.96% in the past year. This is quite bad
Measured over the past years, AGEN shows a quite strong growth in Revenue. The Revenue has been growing by 17.97% on average per year.
EPS 1Y-1314.29%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-17.65%
Revenue growth 1Y-68.96%
Revenue growth 3Y-13.22%
Revenue growth 5Y17.97%
Revenue growth Q2Q20.88%
3.2 Future
The Earnings Per Share is expected to grow by 13.43% on average over the next years. This is quite good.
AGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.67% yearly.
EPS Next Y15.56%
EPS Next 2Y6.9%
EPS Next 3Y6.63%
EPS Next 5Y13.43%
Revenue Next Year13.32%
Revenue Next 2Y12.68%
Revenue Next 3Y15%
Revenue Next 5Y34.67%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.9%
EPS Next 3Y6.63%
5. Dividend
5.1 Amount
No dividends for AGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGENUS INC
NASDAQ:AGEN (9/28/2023, 2:20:34 PM)
1.13
-0.04 (-3.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-06 2023-11-06/bmo
Inst Owners55.71%
Inst Owner Change2.54%
Ins Owners0.47%
Ins Owner Change0.73%
Market Cap428.92M
Analysts87.27
Price Target7.65 (576.99%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.79%
Min EPS beat(2)-2.71%
Max EPS beat(2)1.14%
EPS beat(4)2
Avg EPS beat(4)-2.17%
Min EPS beat(4)-7.77%
Max EPS beat(4)1.14%
Revenue beat(2)2
Avg Revenue beat(2)100166%
Min Revenue beat(2)97625.6%
Max Revenue beat(2)102706%
Revenue beat(4)4
Avg Revenue beat(4)116035%
Min Revenue beat(4)97625.6%
Max Revenue beat(4)156021%
PT rev (1m)-2.09%
PT rev (3m)-0.99%
EPS NQ rev (1m)3.03%
EPS NQ rev (3m)1.03%
EPS NY rev (1m)17.22%
EPS NY rev (3m)18.66%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.9%
Revenue NY rev (1m)3.15%
Revenue NY rev (3m)12.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.26
BVpS-0.25
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 89.38% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 398.04% | ||
| Cap/Sales | 36.58% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | -7.82 |
F-Score1
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)436.8%
Cap/Depr(5y)287.52%
Cap/Sales(3y)23.17%
Cap/Sales(5y)16.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-1314.29%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-17.65%
EPS Next Y15.56%
EPS Next 2Y6.9%
EPS Next 3Y6.63%
EPS Next 5Y13.43%
Revenue growth 1Y-68.96%
Revenue growth 3Y-13.22%
Revenue growth 5Y17.97%
Revenue growth Q2Q20.88%
Revenue Next Year13.32%
Revenue Next 2Y12.68%
Revenue Next 3Y15%
Revenue Next 5Y34.67%
EBIT growth 1Y-511.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.02%
EBIT Next 3Y5.36%
EBIT Next 5Y-0.7%
FCF growth 1Y-38.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.68%
OCF growth 3YN/A
OCF growth 5YN/A